Share this article
Share this article
OSLO, Norway, March 1, 2021 /PRNewswire/ The board of directors of Targovax ASA (OSE:TRVX) ( Targovax or the Company ) has resolved to increase the share capital of the Company following the completion of an exercise period for vested share options under the Company s long-term incentive program for employees. The exercise period for the LTI program commenced on 19 February 2021 at 10:00 hours (CET) and ended on 1 March 2021 at 10:00 hours (CET).
1. Exercise of options
In total, 29,788 options were exercised, giving the option holders the right to subscribe for 29,788 shares, each with a par value of NOK 0.10, of which:
Continued survival benefit in Targovax s ONCOS-102 trial in mesothelioma at the 21-month follow-up
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Continued survival benefit in Targovax s ONCOS-102 trial in mesothelioma at the 21-month follow-up
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
OSLO, Feb. 18, 2021 /PRNewswire/
Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists today at 2:30 PM CET. The Capital Markets Day will feature presentations from executive management and Alexander Shousthari, Clinical Director Melanoma Services at Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible at https://www.targovax.com/en/capital-markets-day-2021/
Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development. We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future. The Capital Markets day will feature presentations updating the market on these aspects.
Myomo, Inc.: Germany s Largest Statutory Health Insurance Company Approves MyoPro
Follows approval by several other major German providers
Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced Techniker Krankenkasse (TK), Germany s largest Statutory Health Insurance (SHI) company, now approves reimbursement of MyoPro on a case-by-case basis. TK covers over 10 Million insured lives and joins the ranks of other major German health insurance providers including BARMER, IKK Classic, regional AOK insurances and several BKK insurances which collectively cover 28 million German lives and have now approved funding for MyoPro.